Lucineia Gainski Danielski

Dr. Lucineia Gainski Danielski

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

10 August 2019 in Brain Sciences
Verified
Journal Article
Open access
PDF file
ASAfonsosi Salgado
Afonsosi Salgado
JSJuliana Stramosk
Juliana Stramosk
DLDaniela D. Ludtke
Daniela D. Ludtke
AKAna C. C. Kuci
Ana C. C. Kuci
DSDaiana C. Salm
Daiana C. Salm
DMDaniel Martins
Daniel Martins
Complex regional pain syndrome type I (CRPS-I) is a chronic painful condition. We investigated whether manual therapy (MT), in a chronic post-ischemia pain (CPIP) model, is capable of reducing pain behavior and oxidative stress. Male Swiss mice were subjected to ischemia-reperfusion (IR) to mimic CRPS-I. Animals received ankle joint mobilization 48h after the IR procedure, and response to mechanical stimuli was evaluated. For biochemical analyses, mitochondrial function as well as oxidative stress thiobarbituric acid reactive substances (TBARS), protein carbonyls, antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT) levels were determined. IR induced mechanical hyperalgesia which was subsequently reduced by acute MT treatment. The concentrations of oxidative stress parameters were increased following IR with MT treatment preventing these increases in malondialdehyde (MDA) and carbonyls protein. IR diminished the levels of SOD and CAT activity and MT treatment prevented this decrease in CAT but not in SOD activity. IR also diminished mitochondrial complex activity, and MT treatment was ineffective in preventing this decrease. In conclusion, repeated sessions of MT resulted in antihyperalgesic effects mediated, at least partially, through the prevention of an increase of MDA and protein carbonyls levels and an improvement in the antioxidant defense system.

19 January 2022 in Experimental Gerontology
Verified
Journal Article
Closed access
WMWillian Margotti
Willian Margotti
MGMariana Pereira de Souza Goldim
Mariana Pereira de Souza Goldim
RMRichard Simon Machado
Richard Simon Machado
EBErick Bagio
Erick Bagio
CDCarlos Dacoregio
Carlos Dacoregio
FPFabricia Petronilho
Fabricia Petronilho

13 November 2024 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
SBSandra Bonfante
Sandra Bonfante
MNMartins Back Netto
Martins Back Netto
AJAloir Neri de Oliveira Junior
Aloir Neri de Oliveira Junior
KMKhiany Mathias
Khiany Mathias
RMRichard Simon Machado
Richard Simon Machado
FPFabricia Petronilho
Fabricia Petronilho


2 November 2022 in Neuroimmunomodulation
Verified
Journal Article
Closed access
PDF file
LJLarissa Joaquim
Larissa Joaquim
AGAmanda Della Giustina
Amanda Della Giustina
RMRichard Simon Machado
Richard Simon Machado
KMKiuanne Lino Lobo Metzker
Kiuanne Lino Lobo Metzker
SBSandra Bonfante
Sandra Bonfante
FPFabricia Petronilho
Fabricia Petronilho
Many coronavirus disease 2019 (COVID-19)-recovered patients report signs and symptoms and are experiencing neurological, psychiatric, and cognitive problems. However, the exact prevalence and outcome of cognitive sequelae is unclear. Even though the severe acute respiratory syndrome coronavirus 2 has target brain cells through binding to angiotensin-converting enzyme 2 (ACE2) receptor in acute infection, several studies indicate the absence of the virus in the brain of many COVID-19 patients who developed neurological disorders. Thus, the COVID-19 mechanisms for stimulating cognitive dysfunction may include neuroinflammation, which is mediated by a sustained systemic inflammation, a disrupted brain barrier, and severe glial reactiveness, especially within the limbic system. This review explores the interplay of infected lungs and brain in COVID-19 and its impact on the cognitive function.